drugset / Trial / NCT04387305

Traumatic Injury Clinical Trial Evaluating Tranexamic Acid in Children: An Efficacy Study

NCT04387305

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Trauma is the leading cause of death and disability in children in the United States. The objective of this study is to evaluate the benefits and harms of tranexamic acid (TXA; a drug that stops bleeding) in severely injured children with hemorrhagic brain and/or torso injuries. Using thromboelastography, we will measure baseline fibrinolysis to assess for treatment effects of TXA at different levels of fibrinolysis.

Timeline

Start
2026-10-01
Primary completion
2031-03-31
Completion
2031-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Tranexamic Acid Small molecule 15 mg/kg
Subject Tranexamic Acid Small molecule 30 mg/kg
Subject Tranexamic Acid Small molecule 45 mg/kg